CN1244335C - Influenze resisting medicine - Google Patents
Influenze resisting medicine Download PDFInfo
- Publication number
- CN1244335C CN1244335C CN 03126177 CN03126177A CN1244335C CN 1244335 C CN1244335 C CN 1244335C CN 03126177 CN03126177 CN 03126177 CN 03126177 A CN03126177 A CN 03126177A CN 1244335 C CN1244335 C CN 1244335C
- Authority
- CN
- China
- Prior art keywords
- radix
- root
- influenza
- rhizoma
- cold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract 3
- 241000756943 Codonopsis Species 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 9
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 claims description 7
- 229940061367 tamiflu Drugs 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 abstract description 16
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 abstract 1
- 235000017491 Bambusa tulda Nutrition 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 241000229179 Ledebouriella Species 0.000 abstract 1
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 abstract 1
- 241000219780 Pueraria Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 229940023019 aconite Drugs 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000011425 bamboo Substances 0.000 abstract 1
- 230000000312 effect on influenza Effects 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 12
- 238000009826 distribution Methods 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 208000008454 Hyperhidrosis Diseases 0.000 description 6
- 206010039101 Rhinorrhoea Diseases 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 208000010753 nasal discharge Diseases 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010063659 Aversion Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 208000013219 diaphoresis Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 201000009240 nasopharyngitis Diseases 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 229960000306 zinc gluconate Drugs 0.000 description 2
- 235000011478 zinc gluconate Nutrition 0.000 description 2
- 239000011670 zinc gluconate Substances 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 description 1
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000009792 yinqiao Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses an anti-influenza medicine which is prepared from raw materials in the following weight proportion: 3 to 15g of cassia twig, 3 to 10g of ginger, 3 to 15g of ledebouriella root, 3 to 7g of aconite root, 9 to 15g of pueraria root, 4.5 to 35g of coptis, 3 to 30g of pilose asiabell root, 10 to 30g of astragalus root, 10 to 30g of rehmannia root, 5 to 15g of white atractylodes rhizome and 5 to 12g of bamboo leaf. The present invention has obvious curative effect on influenza, and treats 300 examples of influenza for several years, wherein the effective rate achieves 99%, and the curative rate achieves reach 95%. The anti-influenza medicine has no side or toxic effect.
Description
Technical field
The present invention relates to the grippal Chinese medicine of a kind of treatment.
Background technology
Flu has influenza and common cold two classes, the former is mainly caused by influenza virus, the latter is then mainly caused by rhinovirus, both sickness rate are all very high, the harm of flu is except causing upper respiratory tract mucosa edema, hyperemia, skin ulcer and other inflammation, also can concurrently cause a series of diseases such as diseases such as myocarditis, pneumonia and asthma, also be to cause one of old man, child patient main causes of death.The medicine of treatment flu at present roughly has three classes, and a coldrex of making for pure Western medicine mainly is the medicine that the infection, antiallergic and the diaphoresis antipyretic composition that use at upper respiratory tract infection and whole body heating paresthesia are made alone or in combination.Two is the compositions of Chinese medicine and Western medicine, and class Chinese medicine and antiallergic class Western medicine cooperate the compound medicine of making to induce sweat.Three is pure Chinese medicinal preparation.More than three class medicines at dissimilar flu certain therapeutic effect is arranged all, but the medicine that contains western medicine composition is big relatively to the side effect of human body, and the curative effect of pure Chinese medicinal preparation can not be satisfactory.
Summary of the invention
The purpose of this invention is to provide a kind of pure Chinese medicinal preparation evident in efficacy.
Technical scheme of the present invention is: a kind of Tamiflu, it is the medicament of being made by following materials of weight proportions: Ramulus Cinnamomi 3-15g, Rhizoma Zingiberis Recens 3-10g, Radix Saposhnikoviae 3-15g, Radix Aconiti Lateralis Preparata 3-7g, Radix Puerariae 9-15g, Rhizoma Coptidis 4.5-35g, Radix Codonopsis 3-30g, Radix Astragali 10-30g, Radix Rehmanniae 10-30g, Rhizoma Atractylodis Macrocephalae 5-15g, Folium Bambusae 6-12g.
The consumption of above-mentioned each Chinese medicine is meant the weight Billy's relation between them, can beat or produce according to the expansion at double of weight Billy relation in the middle of practice, all belongs within the scope of the present invention.
The optimum amount of above-mentioned prescription is:
Ramulus Cinnamomi 8g, Rhizoma Zingiberis Recens 6g, Radix Saposhnikoviae 8g, Radix Aconiti Lateralis Preparata 5g, Radix Puerariae 11g, Rhizoma Coptidis 16g, Radix Codonopsis 16g, Radix Astragali 23g, Radix Rehmanniae 20g, Rhizoma Atractylodis Macrocephalae 10g, Folium Bambusae 9g.
Medicament is powder, oral liquid or piece agent.
The pharmacology explanation of the used component of the present invention:
1, Ramulus Cinnamomi: meridian distribution of property and flavor: hot, sweet, warm, GUIXIN, lung, urinary bladder channel.Effect: relieving the exterior syndrome by diaphoresis warming the meridian for promoting the flow of YANG QI.Use: be used for outer wind and cold exterior syndromes such as aversion to cold, heating, headache.
2, Rhizoma Zingiberis Recens: meridian distribution of property and flavor: suffering, tepor, return lung, spleen channel.Effect: relieving the exterior syndrome by diaphoresis, warming middle-JIAO to arrest vomiting, warming the lung to relieve cough.Use: affection of exogenous wind-cold exterior syndromes such as aversion to cold, heating, headache, nasal obstruction.
3, Radix Saposhnikoviae: meridian distribution of property and flavor: hot, sweet, tepor, return bladder, liver, spleen channel.Effect: expelling pathogenic wind from the body surface, win and wet, the pain relieving spasmolytic is separated the Radix Aconiti Lateralis Preparata poison.Use: be used for outer wind and cold exterior syndromes such as aversion to cold, heating, headache, general pain.
4, Radix Aconiti Lateralis Preparata: meridian distribution of property and flavor: hot, hot, poisonous, GUIXIN, kidney, spleen channel fear Radix Saposhnikoviae.Effect: recuperating depleted YANG and rescuing the patient from collapse, it is supporing yang to mend fire, dispersing cold for relieving pain.Use: be used for cold spontaneous sweating, extremity are fainted contrary, the yang depletion syndrome of faint pulse being about to disappear.
5, Radix Puerariae: meridian distribution of property and flavor: hot, sweet, cool, go into spleen, stomach warp.Effect: relieving muscles diaphoresis, invigorating YANG QI to promote eruption, analgesic promoting the production of body fluid.Use: be used for exterior syndrome due to wind-cold such as heating, headache, lossless, stiff nape and back, aversion to wind.
6, Rhizoma Coptidis: meridian distribution of property and flavor: bitter, cold, GUIXIN, stomach, liver, large intestine channel.Effect: heat clearing and damp drying, eliminating fire and detoxication.Use: be used for the card of the intestines and stomach such as vomiting, dysentery due to damp and hot.
7, Radix Codonopsis: meridian distribution of property and flavor: sweet, put down, return spleen, lung meridian.Effect: invigorating the spleen and replenishing QI, promote the production of body fluid and nourish blood.Use: be used for anorexia and loose stool, QI-insufficiency etc. among the extremity asthenia.
8, the Radix Astragali: meridian distribution of property and flavor: sweet, tepor, return spleen, lung meridian.Effect: tonifying Qi and lifting yang, benefit are defended consolidating superficial resistance, promoting pus discharge and tissue regeneration strengthening, inducing diuresis to remove edema.Use: deficiency of vital energy and physically weak after being ill, with the same usefulness of Radix Ginseng, be used for deficiency of vital energy sun and decline, the fear of cold hyperhidrosis is with the Radix Aconiti Lateralis Preparata compatibility.
9, the Radix Rehmanniae: meridian distribution of property and flavor: sweet, cold, GUIXIN, liver, kidney channel.Effect: clearing away heat and cooling blood, YIN nourishing and the production of body fluid promoting.Use: be used for fever of the body, damp disease heat such as the crimson tongue xerostomia blood disorder of joining the army.
10, the Rhizoma Atractylodis Macrocephalae: meridian distribution of property and flavor: bitter, sweet, warm, return spleen, stomach warp.Effect: air making-up and spleen enlivening, the dampness diuretic, hidroschesis is antiabortive.Use: be used for deficiency-weakness of spleen-QI, due to the dysfunction of the spleen in transportation and transformation, lack of appetite abdominal distention, diarrhea, the card of lassitude.
11, Folium Bambusae: meridian distribution of property and flavor: sweet, light, cold, nontoxic, go into the heart, lung, gallbladder, stomach warp.Effect: clearing heat and relieving fidgetness, the diuresis of promoting the production of body fluid.Use: cure mainly the calentura excessive thirst, pediatric epilepsy scared, cough with dyspnea is told nosebleed, flushed complexion, oliguria with reddish urine, erosion of the oral mucosa tongue boil.
Through day: in healthy energy was deposited, heresy can not be done, and the institute of heresy gathers, its gas must be empty, and motherland's medical science thinks that exopathogen is done in human body, must be the insufficient sign of healthy energy, this side be not limited to traditional principles of formulating prescriptions, an anti-simple heat-clearing and toxic substances removing, clearing away heat and cooling blood, with the prescription of uniqueness, the cool and usefulness of temperature, cold and heat phase 5 reaches QI invigorating and sets upright, and dispelling wind is eliminating evil, set upright and do not grow heresy, eliminating evil and just do not hinder, thus have unique therapeutic effect.
Over several years, treat influenza 300 examples altogether, its effective percentage reaches 99%, and cure rate is 95%, has no side effect, and letter lifts ten for example down:
Case one: what certain, male, 41 years old, government functionary.November calendar year 2001, pharyngalgia was coughed with heating, watery nasal discharge, and whole body is miserable to be chief complaint, and is in hospital a week with flu, and integrative therapy is invalid, this side of clothes of beginning, in the potion, two doses of recoveries from illness.
Case two: Ma, male, 45 years old, medical personnel.Catch a cold in February, 2002, systemic pain, and heating, cough, the sneeze tear are more than, and it is invalid to take Coritab, obeys this side and accuses more for two doses.
Case three: Zhang, male, 43 years old, government functionary.Spring in 2000, heating, cough, weak, watery nasal discharge is in hospital with flu, transfusion penicillin etc., all cards are taken two doses of we as before after five days, and all cards are all healed.
Case four: summer, male, cadre.Because of the habitual common cold several years, all with heating, cough, watery nasal discharge, general malaise, at every turn must several weeks difficult, take three doses of we after, all card recoveries from illness, and the several years no longer catch a cold, illustrate that this side truly has the effect of increase immunity of organisms.
Case five: Cai, male, 40 years old.Caught a cold in 2002, oral Common Cold capsule etc. are invalid, and two doses of symptoms of clothes we disappear entirely.
Case six: Lee, the women, 40 years old, hospital nurse, catch a cold infuse a week in hospital in March, 2002 after still whole body be stranded pain, cough, the YINQIAO sheet is obeyed in heating again, GANMAOTONG etc. still do not heal, take two doses of we after all cards disappear entirely.
Case seven: still certain, women, 35 years old, government functionary.Because of habitual common cold 3 years, June calendar year 2001, cough was infused 20 days all cards as before at county hospital with heating, took remission behind two doses of the we, recovery from illness after three doses.
Case eight: what certain, women, 32 years old, government functionary.In December, 2002 is caught a cold, and generates heat, and watery nasal discharge is shed tears, cough, and systemic pain, invalid with the penicillin transfusion, use the Ceftriaxone reuse instead after three days, symptom can not be alleviated, and fully recovers after our three doses.
Case nine: Di, women, 69 years old, peasant.Catch a cold in January, 2003, cough, and watery nasal discharge is shed tears, and systemic pain is weak, the clothes compound paracetamol and zinc gluconate tablets, medical herbs ten is overpaied etc., and all cards are as usual taken three doses of recoveries from illness of we.
Case ten: pacify certain, women, 35 years old, citizen.In November, 2000, the whole family three people suffer from influenza altogether, all with heating, and cough, watery nasal discharge, general pain are main symptom, the clothes paracetamol, compound paracetamol and zinc gluconate tablets, a couple of days such as erythromycin ethylsuccinate do not heal, and begin to take we, and after two doses, the whole family three people all accuse more.
Our in sum holder thinks: the generation of disease, all be the result of good and evil struggle under certain condition, healthy energy is vigorous, QI and blood is full, solid close outside defending, pathogenic factor is difficult to invade, and disease has no way of taking place, emphasize the leading position of healthy energy in morbidity, but do not get rid of the important function that pathogen takes place disease.Under certain situation, even may play a leading role, described " this gas is to be come, and no matter old and young strong and weak, the person who touches is promptly sick just like " treatise on pestilence "." and for example the atypical pneumonia that takes place of this Beijing is popular, and the generation of multiple infectious disease and popular also has been described, pathogen is an important condition and play mastery reaction.After disease took place, healthy energy and these two kinds of strength of pathogen were not changeless in the body, but the good and evil both sides are in the process of its struggle, the growth and decline prosperity and decline that is taking place in the strength contrast changes, we have strengthening vital QI to eliminate pathogenic factors, and the effect of enhancing human body immunity power is the true essence place of the special effect of treatment influenza.
The present invention has carried out toxicity test in Henan Prov. Inst. of Chinese Medicine ﹠ Pharmacology, and the result is as follows:
Experiment purpose: observe Tamiflu (influenza increase exempt from Ling oral liquid) and can irritate after gastric capacity gives mice toxic reaction that is produced and death condition with Cmax and maximum.
Experiment material: one, be subjected to the reagent thing: influenza increases exempts from Ling oral liquid, 2.5g crude drug/mI, and clinical consumption: oral three times of every day, each 20mL is concentrated into 4g crude drug/mL during experiment.Two, laboratory animal: 20 of Kunming mouses, male and female half and half, body weight 18.8 ± 0.8g is provided the quality certification by Henan Province's Experimental Animal Center: No. the 410115th, the moving word of doctor.
Experimental technique: 20 of Kunming mouses of experiment, male and female half and half, body weight 18.8 ± 0.8g, behind the fasting 12h, (4g crude drug/mL) and maximum can be irritated stomach volume (0.4mL/10g), irritate stomach three times in one day with Cmax, be spaced apart 6h, the conventional raising observed 7 days continuously after the administration at every turn.
Experimental result: after the administration, mice is movable normal, and its hair, the mental status, diet and body weight change etc. there is no unusually, does not have dead in seven days.Limit because of dosage, to increase the mice maximum dosage-feeding of exempting from Ling oral liquid be 480g crude drug/kg body weight so record influenza not measure LD50., is equivalent to 192 times of clinical application amount.
The specific embodiment
Embodiment 1:
By following prescription crude drug is prepared: Ramulus Cinnamomi 8g, Rhizoma Zingiberis Recens 6g, Radix Saposhnikoviae 8g, Radix Aconiti Lateralis Preparata 5g, Radix Puerariae 11g, Rhizoma Coptidis 16g, Radix Codonopsis 16g, Radix Astragali 23g, Radix Rehmanniae 20g, Rhizoma Atractylodis Macrocephalae 10g, Folium Bambusae 9g.
Embodiment 2:
By following prescription crude drug is prepared: Ramulus Cinnamomi 3g, Rhizoma Zingiberis Recens 3g, Radix Saposhnikoviae 3g, Radix Aconiti Lateralis Preparata 3g, Radix Puerariae 9g, Rhizoma Coptidis 4.5g, Radix Codonopsis 3g, Radix Astragali 10g, Radix Rehmanniae 10g, Rhizoma Atractylodis Macrocephalae 5g, Folium Bambusae 5g.
Embodiment 3:
By following prescription crude drug is prepared: Ramulus Cinnamomi 15g, Rhizoma Zingiberis Recens 10g, Radix Saposhnikoviae 15g, Radix Aconiti Lateralis Preparata 7g, Radix Puerariae 15g, Rhizoma Coptidis 435g, Radix Codonopsis 30g, Radix Astragali 30g, Radix Rehmanniae 30g, Rhizoma Atractylodis Macrocephalae 15g, Folium Bambusae 12g.
This medicine can adopt existing method in common to be prepared into powder, oral liquid or piece agent.
Claims (4)
1, a kind of Tamiflu is characterized in that: it is the medicament of being made by following materials of weight proportions: Ramulus Cinnamomi 3-15g, Rhizoma Zingiberis Recens 3-10g, Radix Saposhnikoviae 3-15g, Radix Aconiti Lateralis Preparata 3-7g, Radix Puerariae 9-15g, Rhizoma Coptidis 4.5-35g, Radix Codonopsis 3-30g, Radix Astragali 10-30g, Radix Rehmanniae 10-30g, Rhizoma Atractylodis Macrocephalae 5-15g, Folium Bambusae 5-12g.
2, Tamiflu according to claim 1, it is characterized in that: wherein the weight proportion of each raw material is: Ramulus Cinnamomi 6-12g, Rhizoma Zingiberis Recens 5-8g, Radix Saposhnikoviae 5-10g, Radix Aconiti Lateralis Preparata 4-6g, Radix Puerariae 10-13g, Rhizoma Coptidis 10-25g, Radix Codonopsis 8-20g, Radix Astragali 18-26g, Radix Rehmanniae 16-26g, Rhizoma Atractylodis Macrocephalae 8-12g, Folium Bambusae 6-10g.
3, Tamiflu according to claim 1 is characterized in that: wherein the weight proportion of each raw material is: Ramulus Cinnamomi 8g, Rhizoma Zingiberis Recens 6g, Radix Saposhnikoviae 8g, Radix Aconiti Lateralis Preparata 5g, Radix Puerariae 11g, Rhizoma Coptidis 16g, Radix Codonopsis 16g, Radix Astragali 23g, Radix Rehmanniae 20g, Rhizoma Atractylodis Macrocephalae 10g, Folium Bambusae 9g.
4, Tamiflu according to claim 1 is characterized in that: said medicament is powder, oral liquid or piece agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03126177 CN1244335C (en) | 2003-05-21 | 2003-05-21 | Influenze resisting medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03126177 CN1244335C (en) | 2003-05-21 | 2003-05-21 | Influenze resisting medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1548123A CN1548123A (en) | 2004-11-24 |
| CN1244335C true CN1244335C (en) | 2006-03-08 |
Family
ID=34321889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03126177 Expired - Fee Related CN1244335C (en) | 2003-05-21 | 2003-05-21 | Influenze resisting medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1244335C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101365466A (en) * | 2005-11-16 | 2009-02-11 | 纳特比奥控股有限公司 | Zingiber plant extract |
| CN101366510B (en) * | 2008-09-03 | 2012-04-25 | 李富祥 | Infused beverage capable of preventing cold |
| CN113521232B (en) * | 2020-04-21 | 2024-07-02 | 天士力医药集团股份有限公司 | A Chinese medicinal composition containing Atractylodis rhizoma |
-
2003
- 2003-05-21 CN CN 03126177 patent/CN1244335C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1548123A (en) | 2004-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100998843A (en) | Medicinal composition for treating cholecystitis | |
| CN102058767B (en) | Chinese medicine for treating senile chronic bronchitis and method for preparing pills thereof | |
| CN103520680A (en) | Traditional Chinese medicine for treating acute heart failure | |
| CN103182019A (en) | Traditional Chinese medicine composition for treating ROU (recurrent oral ulcer) | |
| CN102579610B (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN104147572A (en) | Cold and fever wind-dispelling and heat-dispersing preparation and preparation method | |
| CN1244335C (en) | Influenze resisting medicine | |
| CN101274024A (en) | Pharmaceutical compositions for curing toothache | |
| CN102430105A (en) | Traditional Chinese medicine composition for treating chronic gastritis | |
| CN102416121B (en) | Application of medicinal composition in preparation of medicaments for treating gastric ulcer | |
| CN101912567A (en) | Chinese medicinal prescription for treating chronic myocarditis | |
| CN102430073B (en) | Medicinal composition for treating peptic ulcer | |
| CN103212020A (en) | Traditional Chinese medicine composition for treating functional dyspepsia | |
| CN102416120B (en) | Application of medicinal composition in preparation of medicament for treating erosive gastritis | |
| CN1616041A (en) | Chinese medicine composition for treating chronic ulcerative colitis | |
| CN1686500A (en) | Chinese medicinal preparation for treating breast impediment | |
| CN1562232A (en) | Medication for curing ulcerationd of oral cavity | |
| CN102416122B (en) | Application of medicinal composition in preparation of medicaments for treating duodenal ulcer | |
| CN1537559A (en) | Traditional Chinese medicine for treating AIDS | |
| CN117717594B (en) | Traditional Chinese medicine composition for treating lumbar muscle degeneration as well as preparation method and application thereof | |
| CN103599185B (en) | A kind of Chinese medicine composition being used for the treatment of headache | |
| CN100348252C (en) | Chinese medicinal product for protecting liver and freezing bowel | |
| CN1309412C (en) | Medicine composition for treating AIDS and preparing method thereof | |
| CN100411672C (en) | A medicinal composition for treatment of psoriasis | |
| CN101224295A (en) | Chinese traditional medicine compounds for treating digestive system tumor and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060308 Termination date: 20100521 |